Finding the Right Treatments for the Right Patients

Finding the Right Treatments for the Right Patients

Deploying an RNA-based informatics pipeline to identify drug responder populations and advance the development of precision cancer therapeutics

Translating the Complexity of Tumor Biology

Translating the Complexity of Tumor Biology

GeneCentric’s RNA-based diagnostics capture the actual response phenotype to give a more complete picture than traditional DNA testing

Delivering Greater Precision to Precision Medicine

Delivering Greater Precision to Precision Medicine

Accelerating the development of precision cancer therapeutics through a deep understanding of the tumor and immune microenvironment using the rT(I)ME Explorer Platform.

Advancing precision medicine through RNA-based diagnostics

GeneCentric is unwinding the complexities of the Tumor and Immune MicroEnvironment (T(I)ME) and translating those insights into actionable genomic signatures of drug response and new target identification for cancer.

Our RNA-based rT(I)ME Explorer Platform uses advanced computational biology informatics that enable the development of robust and clinically impactful gene signatures and related diagnostics for selecting the right patients for the right therapy.

LEARN MORE

Diagnostics powered by the rT(I)ME Explorer Platform

We are building a pipeline of prognostic and predictive response signatures and related diagnostics for both prevalent and complex cancers with high unmet medical need.

LEARN MORE

Biopharma partnerships fueling drug development

GeneCentric collaborates with some of the world’s leading research and development organizations and commercial reference labs. By bringing together our unique strengths and proprietary technology for RNA-based diagnostics, we rapidly and efficiently translate the most promising science and advance drug development to deliver new hope to those fighting cancer.

LEARN MORE
VIEW ALL RECENT NEWS & EVENTS